Takahiro Kirisawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Takahiro Kirisawa has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
Ayumu Matsuda
Department of Urology and Retroperitoneal Surgery National Cancer Center Hospital Tokyo Japan
5 shared publicationsMotokiyo Komiyama
Department of Urology and Retroperitoneal Surgery National Cancer Center Hospital Tokyo Japan
5 shared publicationsTomoya Okuno
Department of Urology and Retroperitoneal Surgery National Cancer Center Hospital Tokyo Japan
5 shared publicationsEijiro Nakamura
Department of Urology and Retroperitoneal Surgery National Cancer Center Hospital Tokyo Japan
4 shared publicationsHiroki Hagimoto
Department of Urology and Retroperitoneal Surgery National Cancer Center Hospital Tokyo Japan
4 shared publicationsHiroyuki Fujimoto
Department of Urology and Retroperitoneal Surgery National Cancer Center Hospital Tokyo Japan
4 shared publications
Latest Publications
- 11 July 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (7) , e70561
Streamlining Informed Consent for Urinary Diversion Using an Artificial Intelligence‐Generated Avatar System: A Novel Approach to Physician Work‐Style Reform
- 11 July 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (7) , e70561
Streamlining Informed Consent for Urinary Diversion Using an Artificial Intelligence‐Generated Avatar System: A Novel Approach to Physician Work‐Style Reform
- 19 May 2025
- Published by Wiley in International Journal of Urology
- Vol. 32 (9) , 1180-1185
Outcomes of Patients With International Germ Cell Cancer Collaborative Group Good Prognosis Metastatic Seminoma Undergoing De‐Escalation Chemotherapy: A Single‐Center Retrospective Study
Objective: To compare the survival outcomes of de‐escalation chemotherapy with those of standard first‐line chemotherapy in patients with International Germ Cell Cancer Collaborative Group (IGCCCG) good prognosis metastatic seminoma. Methods: The cohort of this retrospective, observational, single‐center study comprised 35 patients with clinical Stage I (CSI)‐relapsed or de novo IGCCCG good prognosis metastatic seminoma who had undergone induction chemotherapy at our institution between 2007 and 2021. Patients were allocated to standard or de‐escalation therapy groups according to average relative dose intensity (ARDI) of induction chemotherapy: ARDI ≥ 90 and ARDI < 90. Overall and recurrence‐free survival were compared between these groups using Kaplan–Meier curves and the log‐rank test. Results: The de‐escalation therapy regimen included three cycles of etoposide and cisplatin (66.7%). Overall and relapse‐free survival of patients undergoing de‐escalation therapy and that of patients undergoing standard therapy were comparable. In addition, rates of adverse events, including hearing impairment and peripheral neuropathy induced by cisplatin‐containing chemotherapy, were slightly, but not significantly, lower in the de‐escalation therapy group than in the standard therapy group. Conclusions: Our findings provide a preliminary experimental basis for the development of de‐escalation therapy for IGCCCG good prognosis metastatic seminoma. If sufficient tumor regression is achieved, de‐escalation therapy incorporating three cycles of etoposide/cisplatin therapy could be considered acceptable for patients with relatively low metastatic tumor burdens, such as those with Stage II CSI‐relapsed seminoma. Further studies to validate the efficacy of de‐escalation therapy are warranted.
- 19 May 2025
- Published by Wiley in International Journal of Urology
- Vol. 32 (9) , 1180-1185
Outcomes of Patients With International Germ Cell Cancer Collaborative Group Good Prognosis Metastatic Seminoma Undergoing De‐Escalation Chemotherapy: A Single‐Center Retrospective Study
Objective: To compare the survival outcomes of de‐escalation chemotherapy with those of standard first‐line chemotherapy in patients with International Germ Cell Cancer Collaborative Group (IGCCCG) good prognosis metastatic seminoma. Methods: The cohort of this retrospective, observational, single‐center study comprised 35 patients with clinical Stage I (CSI)‐relapsed or de novo IGCCCG good prognosis metastatic seminoma who had undergone induction chemotherapy at our institution between 2007 and 2021. Patients were allocated to standard or de‐escalation therapy groups according to average relative dose intensity (ARDI) of induction chemotherapy: ARDI ≥ 90 and ARDI < 90. Overall and recurrence‐free survival were compared between these groups using Kaplan–Meier curves and the log‐rank test. Results: The de‐escalation therapy regimen included three cycles of etoposide and cisplatin (66.7%). Overall and relapse‐free survival of patients undergoing de‐escalation therapy and that of patients undergoing standard therapy were comparable. In addition, rates of adverse events, including hearing impairment and peripheral neuropathy induced by cisplatin‐containing chemotherapy, were slightly, but not significantly, lower in the de‐escalation therapy group than in the standard therapy group. Conclusions: Our findings provide a preliminary experimental basis for the development of de‐escalation therapy for IGCCCG good prognosis metastatic seminoma. If sufficient tumor regression is achieved, de‐escalation therapy incorporating three cycles of etoposide/cisplatin therapy could be considered acceptable for patients with relatively low metastatic tumor burdens, such as those with Stage II CSI‐relapsed seminoma. Further studies to validate the efficacy of de‐escalation therapy are warranted.
- 23 October 2024
- Published by Wiley in Pathology International
- Vol. 74 (12) , 714-717
Widespread benign HNF1β‐positive solid nests from the urethral diverticulum to the bladder neck: Is it a mesonephric remnant?
- 23 October 2024
- Published by Wiley in Pathology International
- Vol. 74 (12) , 714-717
Widespread benign HNF1β‐positive solid nests from the urethral diverticulum to the bladder neck: Is it a mesonephric remnant?
- Open Access
- 1 September 2024
- Published by Wolters Kluwer Health in JU Open Plus
- Vol. 2 (9)
Prognostic Factors for Patients With Urachal Carcinoma Undergoing Radical Surgery: Risk Stratification for Future Prospects of Precision Oncology
Purpose: To determine poor prognostic factors for patients with urachal carcinoma (UrC) undergoing radical surgery; identify candidates for precision oncology, including adjuvant therapy; and improve survival outcome of this rare malignant disease. Materials and Methods: We included 51 patients with UrC who underwent radical or partial cystectomy at our institution between 1991 and 2023. Kaplan-Meier curves and log-rank test were performed to estimate overall survival (OS) and recurrence-free survival by applying the Ontario staging system. A Cox proportional hazard regression model was used for multivariate analysis to evaluate prognostic factors for patients undergoing radical surgery. Results: Univariate and multivariate analyses showed that tumor involvement of perivesical fat (Ontario stage T3) and tumor grade were significant prognostic factors for OS. Tumor involvement of perivesical fat was a common factor for both OS and recurrence-free survival. Patients with both adverse factors showed significantly poor OS compared with those with 1 or no adverse factors (P = .014 and .0014, respectively). Conclusions: Tumor involvement of perivesical fat and tumor grade were strong predictors of survival outcome. Adjuvant therapy might be indicated in patients with high recurrence risk. Our results warrant further, multidisciplinary investigation into the impact of precision oncology for patients with UrC and high recurrence risk.
- 1 September 2024
- Published by Wolters Kluwer Health in JU Open Plus
- Vol. 2 (9)
Open AccessPrognostic Factors for Patients With Urachal Carcinoma Undergoing Radical Surgery: Risk Stratification for Future Prospects of Precision Oncology
Purpose: To determine poor prognostic factors for patients with urachal carcinoma (UrC) undergoing radical surgery; identify candidates for precision oncology, including adjuvant therapy; and improve survival outcome of this rare malignant disease. Materials and Methods: We included 51 patients with UrC who underwent radical or partial cystectomy at our institution between 1991 and 2023. Kaplan-Meier curves and log-rank test were performed to estimate overall survival (OS) and recurrence-free survival by applying the Ontario staging system. A Cox proportional hazard regression model was used for multivariate analysis to evaluate prognostic factors for patients undergoing radical surgery. Results: Univariate and multivariate analyses showed that tumor involvement of perivesical fat (Ontario stage T3) and tumor grade were significant prognostic factors for OS. Tumor involvement of perivesical fat was a common factor for both OS and recurrence-free survival. Patients with both adverse factors showed significantly poor OS compared with those with 1 or no adverse factors (P = .014 and .0014, respectively). Conclusions: Tumor involvement of perivesical fat and tumor grade were strong predictors of survival outcome. Adjuvant therapy might be indicated in patients with high recurrence risk. Our results warrant further, multidisciplinary investigation into the impact of precision oncology for patients with UrC and high recurrence risk.
- 1 May 2024
- Published by Wiley in International Journal of Urology
- Vol. 31 (7) , 804-812
Clinical characteristics and survival outcomes of elderly patients with de novo metastatic germ cell tumors
Objectives: To determine the outcomes for elderly patients with de novo metastatic germ cell tumors and the influence of patient age on adherence to standard chemotherapy.Methods: A total of 150 patients who were initially diagnosed with metastatic germ cell tumors and treated at our institution between 2007 and 2021 were included. Patients were classified according to three age groups: aged <40, 40–49, and ≥50 years. Clinicopathological features, adherence to standard first‐line chemotherapy, overall survival, and disease‐free survival were compared between these groups. We also analyzed the outcomes of patients who received low‐intensity induction chemotherapy due to adverse events and/or comorbidities.Results: There was no significant difference in any of the survival outcomes and in the rate of adherence to standard first‐line chemotherapy between the three age groups, although elderly patients with intermediate/poor prognosis group tended to receive less‐intense chemotherapies. The rate of febrile neutropenia as a chemotherapy‐related adverse event was significantly higher in patients aged ≥50 years. No statistical significance in survival outcomes was detected between the group of patients who received relatively low‐intensity induction chemotherapy and those who received adequately intensive planned chemotherapy.Conclusions: The adherence rate of standard fist‐line chemotherapy of elderly patients is almost comparable to that of younger patients, although some adverse events should be carefully managed. Even elderly patients with metastatic germ cell tumors can aim for equivalently good survival outcome like younger populations, with effort to adhere to standard chemotherapy.
- 1 May 2024
- Published by Wiley in International Journal of Urology
- Vol. 31 (7) , 804-812
Clinical characteristics and survival outcomes of elderly patients with de novo metastatic germ cell tumors
Objectives: To determine the outcomes for elderly patients with de novo metastatic germ cell tumors and the influence of patient age on adherence to standard chemotherapy.Methods: A total of 150 patients who were initially diagnosed with metastatic germ cell tumors and treated at our institution between 2007 and 2021 were included. Patients were classified according to three age groups: aged <40, 40–49, and ≥50 years. Clinicopathological features, adherence to standard first‐line chemotherapy, overall survival, and disease‐free survival were compared between these groups. We also analyzed the outcomes of patients who received low‐intensity induction chemotherapy due to adverse events and/or comorbidities.Results: There was no significant difference in any of the survival outcomes and in the rate of adherence to standard first‐line chemotherapy between the three age groups, although elderly patients with intermediate/poor prognosis group tended to receive less‐intense chemotherapies. The rate of febrile neutropenia as a chemotherapy‐related adverse event was significantly higher in patients aged ≥50 years. No statistical significance in survival outcomes was detected between the group of patients who received relatively low‐intensity induction chemotherapy and those who received adequately intensive planned chemotherapy.Conclusions: The adherence rate of standard fist‐line chemotherapy of elderly patients is almost comparable to that of younger patients, although some adverse events should be carefully managed. Even elderly patients with metastatic germ cell tumors can aim for equivalently good survival outcome like younger populations, with effort to adhere to standard chemotherapy.
- 21 December 2023
- Published by Springer Nature in International Cancer Conference Journal
- Vol. 13 (2) , 98-102
Significant reduction in burden of metastatic disease by intermittent docetaxel therapy in a patient with castration-resistant prostate cancer
Intermittent docetaxel therapy (IDT) is rarely used nowadays as a treatment option for men with metastatic castration-resistant prostate cancer (mCRPC) because of the widespread availability of androgen receptor axis-targeted therapy, which is less toxic. Therefore, there is limited information available on whether IDT has a clinical benefit in the treatment of men with mCRPC. This report describes the case of a 66-year-old man with a diagnosis of cT2N1M0 prostate cancer who underwent neoadjuvant combined androgen blockade and whole-pelvis radiation therapy. However, the tumor had progressed to mCRPC with metastasis to the bladder and a left pelvic lymph node within 2 years. Docetaxel had been administered as first-line chemotherapy, and the patient achieved a complete response in terms of the bladder metastasis. Docetaxel was stopped after 15 cycles. When a durable response had been maintained for more than 2 years, during which only androgen deprivation therapy was administered, the patient was switched to observation only. However, his prostate-specific antigen level gradually increased. Abiraterone was started as second-line therapy, during which there was a rapid increase in the PSA level. Computed tomography revealed further enlargement of the left pelvic lymph node, bladder metastasis, metastasis to the left common iliac lymph nodes, and several disseminated nodules around the bladder. Docetaxel was reintroduced as IDT for third-line therapy, and a complete response was achieved for all metastases, with the exception of the metastasis in the left pelvic lymph node. Thus far, the patient has survived for more than 7 years after starting docetaxel as first-line therapy for mCRPC. IDT is potentially useful in a subgroup of patients with mCRPC and could achieve long-term survival. Comprehensive genomic profiling may help physicians to select patients with mCRPC who are more likely to benefit from docetaxel than other systemic therapy.
- 21 December 2023
- Published by Springer Nature in International Cancer Conference Journal
- Vol. 13 (2) , 98-102
Significant reduction in burden of metastatic disease by intermittent docetaxel therapy in a patient with castration-resistant prostate cancer
Intermittent docetaxel therapy (IDT) is rarely used nowadays as a treatment option for men with metastatic castration-resistant prostate cancer (mCRPC) because of the widespread availability of androgen receptor axis-targeted therapy, which is less toxic. Therefore, there is limited information available on whether IDT has a clinical benefit in the treatment of men with mCRPC. This report describes the case of a 66-year-old man with a diagnosis of cT2N1M0 prostate cancer who underwent neoadjuvant combined androgen blockade and whole-pelvis radiation therapy. However, the tumor had progressed to mCRPC with metastasis to the bladder and a left pelvic lymph node within 2 years. Docetaxel had been administered as first-line chemotherapy, and the patient achieved a complete response in terms of the bladder metastasis. Docetaxel was stopped after 15 cycles. When a durable response had been maintained for more than 2 years, during which only androgen deprivation therapy was administered, the patient was switched to observation only. However, his prostate-specific antigen level gradually increased. Abiraterone was started as second-line therapy, during which there was a rapid increase in the PSA level. Computed tomography revealed further enlargement of the left pelvic lymph node, bladder metastasis, metastasis to the left common iliac lymph nodes, and several disseminated nodules around the bladder. Docetaxel was reintroduced as IDT for third-line therapy, and a complete response was achieved for all metastases, with the exception of the metastasis in the left pelvic lymph node. Thus far, the patient has survived for more than 7 years after starting docetaxel as first-line therapy for mCRPC. IDT is potentially useful in a subgroup of patients with mCRPC and could achieve long-term survival. Comprehensive genomic profiling may help physicians to select patients with mCRPC who are more likely to benefit from docetaxel than other systemic therapy.
- Open Access
- 27 March 2023
- Published by Wolters Kluwer Health in Current Urology
- Vol. 18 (2) , 122-127
Which characteristics are associated with changes in medication status for lower urinary tract symptoms among patients with prostate cancer receiving external beam radiotherapy?
Background: We clarified the predictive factors for changes in the status of medications for lower urinary tract symptoms (LUTS) 2 years after local radiotherapy for nonmetastatic prostate cancer. Materials and methods: We retrospectively included patients who underwent local external radiotherapy for nonmetastatic prostate cancer in 8 institutions between April 2001 and March 2016. Patients were divided into the medication and no-medication group based on the use of drugs for LUTS before radiotherapy. We defined improvement of LUTS as when the patient did not require medication for LUTS at 24 months after radiotherapy in the medication group and as deterioration when medication was required in the no-medication group. Logistic regression analysis was used to evaluate predictive factors for changes in medication status. Results: Altogether, 505 patients were divided into a no-medication group (n = 352) and a medication group (n = 153). The number of patients with deterioration and improvement in LUTS was 49 (14%) and 36 (23%), respectively. In the multivariate analysis, the predictive variables for deterioration were the International Prostate Symptom Score (≥8; odds ratio [OR], 2.21; p = 0.014) and the biopsy Gleason score (≤3 + 4 = 7; OR, 2.430; p = 0.008) in the no-medication group, whereas those for improvement were age (p = 0.002), the quality of life score (p = 0.028), and a positive biopsy core rate (≥50%; OR, 2.530; p = 0.027) in the medication group. Conclusions: These predictive factors for changes in the status of medications for LUTS at 2 years after external radiotherapy may help determine the definitive therapy for nonmetastatic prostate cancer.
- 27 March 2023
- Published by Wolters Kluwer Health in Current Urology
- Vol. 18 (2) , 122-127
Open AccessWhich characteristics are associated with changes in medication status for lower urinary tract symptoms among patients with prostate cancer receiving external beam radiotherapy?
Background: We clarified the predictive factors for changes in the status of medications for lower urinary tract symptoms (LUTS) 2 years after local radiotherapy for nonmetastatic prostate cancer. Materials and methods: We retrospectively included patients who underwent local external radiotherapy for nonmetastatic prostate cancer in 8 institutions between April 2001 and March 2016. Patients were divided into the medication and no-medication group based on the use of drugs for LUTS before radiotherapy. We defined improvement of LUTS as when the patient did not require medication for LUTS at 24 months after radiotherapy in the medication group and as deterioration when medication was required in the no-medication group. Logistic regression analysis was used to evaluate predictive factors for changes in medication status. Results: Altogether, 505 patients were divided into a no-medication group (n = 352) and a medication group (n = 153). The number of patients with deterioration and improvement in LUTS was 49 (14%) and 36 (23%), respectively. In the multivariate analysis, the predictive variables for deterioration were the International Prostate Symptom Score (≥8; odds ratio [OR], 2.21; p = 0.014) and the biopsy Gleason score (≤3 + 4 = 7; OR, 2.430; p = 0.008) in the no-medication group, whereas those for improvement were age (p = 0.002), the quality of life score (p = 0.028), and a positive biopsy core rate (≥50%; OR, 2.530; p = 0.027) in the medication group. Conclusions: These predictive factors for changes in the status of medications for LUTS at 2 years after external radiotherapy may help determine the definitive therapy for nonmetastatic prostate cancer.
- Open Access
- 29 December 2021
- Published by Wiley in IJU Case Reports
- Vol. 5 (2) , 122-125
Cytoreductive robot‐assisted prostatectomy for systemic prostate rhabdomyosarcoma presenting as urinary retention
Introduction: In adults, rhabdomyosarcoma of the prostate is extremely rare and has an unfavorable prognosis. These patients frequently experience urinary obstruction, and cysto‐prostatectomy is a mainstay treatment for localized disease. In contrast, treatment strategies for the primary site for metastatic disease remain controversial. To our knowledge, robot‐assisted surgery for the primary tumor has not been reported.Case presentation: A 26‐year‐old man complained of dysuria. Magnetic resonance imaging showed enlarged prostate and computed tomography revealed a pulmonary metastasis. Transurethral resection of the prostate led to the diagnosis of rhabdomyosarcoma. After chemotherapy, robot‐assisted prostatectomy was performed to relieve obstructive urinary symptoms. Although disease progression in the metastatic site was observed after the surgery, urinary obstruction did not occur and quality of life was well maintained.Conclusion: Robot‐assisted prostatectomy may be beneficial both for local disease control and palliation of voiding impairment among selected patients with systemic rhabdomyosarcoma of the prostate.
- 29 December 2021
- Published by Wiley in IJU Case Reports
- Vol. 5 (2) , 122-125
Open AccessCytoreductive robot‐assisted prostatectomy for systemic prostate rhabdomyosarcoma presenting as urinary retention
Introduction: In adults, rhabdomyosarcoma of the prostate is extremely rare and has an unfavorable prognosis. These patients frequently experience urinary obstruction, and cysto‐prostatectomy is a mainstay treatment for localized disease. In contrast, treatment strategies for the primary site for metastatic disease remain controversial. To our knowledge, robot‐assisted surgery for the primary tumor has not been reported.Case presentation: A 26‐year‐old man complained of dysuria. Magnetic resonance imaging showed enlarged prostate and computed tomography revealed a pulmonary metastasis. Transurethral resection of the prostate led to the diagnosis of rhabdomyosarcoma. After chemotherapy, robot‐assisted prostatectomy was performed to relieve obstructive urinary symptoms. Although disease progression in the metastatic site was observed after the surgery, urinary obstruction did not occur and quality of life was well maintained.Conclusion: Robot‐assisted prostatectomy may be beneficial both for local disease control and palliation of voiding impairment among selected patients with systemic rhabdomyosarcoma of the prostate.
- Open Access
- 27 May 2021
- Published by Springer Nature in International Cancer Conference Journal
- Vol. 10 (3) , 248-253
Bladder metastasis without hematuria, following radiation therapy for lung adenocarcinoma
Bladder metastasis from lung adenocarcinoma is extremely rare. Unlike primary bladder urothelial tumors, the initial symptoms of this disease vary, and include pelvic pain, dysuria, and hematuria. There are few reports on cases without microscopic hematuria. An 86-year-old woman with a previous history of radiation therapy for lung adenocarcinoma complained of urinary frequency. A urinalysis was negative for hematuria and pyuria; thus, overactive bladder was suspected. However, the patient’s symptom worsened considerably, and cystoscopy revealed bladder tumor. Transurethral resection of the bladder tumor was performed. Based on the histological, immunohistochemical examination and clinical history, the final pathological diagnosis was bladder metastasis from lung adenocarcinoma. The patient died 19 days after the operation due to severe disease progression. In this rare case, a patient with bladder metastasis from lung adenocarcinoma did not show microscopic hematuria. Cystoscopy and computed tomography helped to make a rapid and accurate diagnosis.
- 27 May 2021
- Published by Springer Nature in International Cancer Conference Journal
- Vol. 10 (3) , 248-253
Open AccessBladder metastasis without hematuria, following radiation therapy for lung adenocarcinoma
Bladder metastasis from lung adenocarcinoma is extremely rare. Unlike primary bladder urothelial tumors, the initial symptoms of this disease vary, and include pelvic pain, dysuria, and hematuria. There are few reports on cases without microscopic hematuria. An 86-year-old woman with a previous history of radiation therapy for lung adenocarcinoma complained of urinary frequency. A urinalysis was negative for hematuria and pyuria; thus, overactive bladder was suspected. However, the patient’s symptom worsened considerably, and cystoscopy revealed bladder tumor. Transurethral resection of the bladder tumor was performed. Based on the histological, immunohistochemical examination and clinical history, the final pathological diagnosis was bladder metastasis from lung adenocarcinoma. The patient died 19 days after the operation due to severe disease progression. In this rare case, a patient with bladder metastasis from lung adenocarcinoma did not show microscopic hematuria. Cystoscopy and computed tomography helped to make a rapid and accurate diagnosis.
- Open Access
- 1 January 2021
- Published by Japanese Society for Pediatric Nephrology in Japanese journal of pediatric nephrology
- Vol. 34 (1) , 33-37
Examination of the necessity of voiding cystourethrography in neonates with multicystic dysplastic kidney
多囊胞性異形成腎(multicystic dysplastic kidney: MCDK) 患児に対する排尿時膀胱尿道造影(voiding cystourethrography: VCUG)の施行意義を後方視的に検討した.当院,国立病院機構北海道医療センターの 2 施設の MCDK 患児 36 例を対象にした.Vesicoureteral reflux(VUR) は 6 例(16.7%)に認めた.6 例中 5 例が grade III であり 1 例が grade I であった.全例に予防的抗菌薬投与を行ったが,grade III の症例のうち 2 例で有熱性尿路感染症を発症した.VUR が改善しなかった 1 例を追加した 3 例にデフラックス注入療法を施行し VUR は消失した.健側腎エコーの異常所見と VUR 合併有無について検討したが,相関は得られなかった.MCDK は機能的単腎であることから,逆流性腎症に伴う将来的な腎機能低下の進行を防ぐため,MCDK 患児に VCUG を施行する意義はあると考えられた.
- 1 January 2021
- Published by Japanese Society for Pediatric Nephrology in Japanese journal of pediatric nephrology
- Vol. 34 (1) , 33-37
Open AccessExamination of the necessity of voiding cystourethrography in neonates with multicystic dysplastic kidney
多囊胞性異形成腎(multicystic dysplastic kidney: MCDK) 患児に対する排尿時膀胱尿道造影(voiding cystourethrography: VCUG)の施行意義を後方視的に検討した.当院,国立病院機構北海道医療センターの 2 施設の MCDK 患児 36 例を対象にした.Vesicoureteral reflux(VUR) は 6 例(16.7%)に認めた.6 例中 5 例が grade III であり 1 例が grade I であった.全例に予防的抗菌薬投与を行ったが,grade III の症例のうち 2 例で有熱性尿路感染症を発症した.VUR が改善しなかった 1 例を追加した 3 例にデフラックス注入療法を施行し VUR は消失した.健側腎エコーの異常所見と VUR 合併有無について検討したが,相関は得られなかった.MCDK は機能的単腎であることから,逆流性腎症に伴う将来的な腎機能低下の進行を防ぐため,MCDK 患児に VCUG を施行する意義はあると考えられた.